vs
Side-by-side financial comparison of Seres Therapeutics, Inc. (MCRB) and ScanTech AI Systems Inc. (STAI). Click either name above to swap in a different company.
ScanTech AI Systems Inc. is the larger business by last-quarter revenue ($631.0K vs $351.0K, roughly 1.8× Seres Therapeutics, Inc.). Seres Therapeutics, Inc. runs the higher net margin — 2337.3% vs -1532.9%, a 3870.2% gap on every dollar of revenue.
Seres Therapeutics is a clinical-stage biotechnology company focused on developing novel microbiome-based therapeutic medicines. It targets unmet needs across infectious, inflammatory, and metabolic disease areas, with lead candidates for recurrent Clostridioides difficile infection. It operates primarily in the U.S. and partners with global pharma firms to advance its pipeline.
MCRB vs STAI — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $351.0K | $631.0K |
| Net Profit | $8.2M | $-9.7M |
| Gross Margin | — | 27.6% |
| Operating Margin | -6403.7% | -773.2% |
| Net Margin | 2337.3% | -1532.9% |
| Revenue YoY | — | — |
| Net Profit YoY | -90.8% | — |
| EPS (diluted) | $0.94 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $351.0K | $631.0K | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $346.1K | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
| Q3 25 | $8.2M | $-9.7M | ||
| Q2 25 | — | $-6.9M | ||
| Q1 25 | — | $-17.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $88.8M | — | ||
| Q2 24 | $-32.9M | — | ||
| Q1 24 | $-40.1M | — |
| Q3 25 | — | 27.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 29.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | -6403.7% | -773.2% | ||
| Q2 25 | — | -440.1% | ||
| Q1 25 | — | -4503.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | 2337.3% | -1532.9% | ||
| Q2 25 | — | -785.1% | ||
| Q1 25 | — | -5174.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | $0.94 | $-0.16 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | — | ||
| Q3 24 | $11.63 | — | ||
| Q2 24 | $-4.34 | — | ||
| Q1 24 | $-5.49 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $47.6M | — |
| Total DebtLower is stronger | — | $17.7M |
| Stockholders' EquityBook value | $43.7M | — |
| Total Assets | $143.5M | $5.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $47.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $30.8M | — | ||
| Q3 24 | $66.8M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $111.2M | — |
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $17.7M | ||
| Q1 25 | — | $17.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $110.0M | — | ||
| Q1 24 | $110.0M | — |
| Q3 25 | $43.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $13.8M | — | ||
| Q3 24 | $23.9M | — | ||
| Q2 24 | $-87.1M | — | ||
| Q1 24 | $-59.7M | — |
| Q3 25 | $143.5M | $5.1M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | — | $5.1M | ||
| Q4 24 | $139.8M | — | ||
| Q3 24 | $178.7M | — | ||
| Q2 24 | $321.7M | — | ||
| Q1 24 | $341.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.2M | $-758.5K |
| Free Cash FlowOCF − Capex | $2.2M | — |
| FCF MarginFCF / Revenue | 626.2% | — |
| Capex IntensityCapex / Revenue | 2.3% | 0.0% |
| Cash ConversionOCF / Net Profit | 0.27× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-221.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $2.2M | $-758.5K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.2M | ||
| Q4 24 | $-148.6M | — | ||
| Q3 24 | $-34.7M | — | ||
| Q2 24 | $-39.8M | — | ||
| Q1 24 | $-35.2M | — |
| Q3 25 | $2.2M | — | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.2M | ||
| Q4 24 | $-149.0M | — | ||
| Q3 24 | $-34.8M | — | ||
| Q2 24 | $-39.9M | — | ||
| Q1 24 | $-35.3M | — |
| Q3 25 | 626.2% | — | ||
| Q2 25 | — | -166.0% | ||
| Q1 25 | — | -623.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | 2.3% | 0.0% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | 0.27× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
